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Abstract 
Introduction: The aim of the study was to analyse the influence of renal impair-
ment on the pharmacokinetic parameters (PK) of mycophenolic acid (MPA) and
its glucuronide metabolite (MPAG) in renal transplant recipients.
Material and methods: The study included 43 adult patients during the main-
tenance period (> 6 months) following renal transplantation, treated with
mycophenolate mofetil (MMF), calcineurin inhibitors (CNI) (tacrolimus or
cyclosporine) and steroids. The study compared patients with normal renal func-
tion (n = 17; creatinine clearance (Ccr) > 60 ml/min) and with renal impairment
(n = 26; Ccr < 60 ml/min). Areas under the 4-h curve (AUC0-4 h) of MPA and MPAG
were determined using a validated HPLC method.
Results: The renal impairment group showed significantly increased AUC0-4 h
and pre-dose (C0) for MPAG compared to patients with normal renal function
and increased MPA C0. However, there was no significant difference in MPA
AUC0-4 h between patients with renal impairment and patients with normal
renal function. In multivariate analysis some MPA and MPAG PK parameters
were correlated with sex, CNI co-administered and body weight. 
Conclusions: Although MPAG is an inactive metabolite, its accumulation in
patients with renal impairment can be unfavourable. The results of our study
indicate that solely MPA C0 determination in patients receiving MMF may be
insufficient in clinical practice because of great inter-patient variability of this
PK parameter caused mainly by enterohepatic recirculation. 
Key words: kidney transplantation, immunosuppressive agents, mycophenolate
mofetil metabolites, pharmacokinetics, renal impairment.
Introduction 
Mycophenolate mofetil (MMF, CellCept®) is the most widely used
antiproliferative immunosuppressive drug in patients after solid organ
transplantation, often co-administered with calcineurin inhibitors (CNI)
and corticosteroids [1].
Pharmacologically inactive MMF after oral administration is rapidly and
entirely hydrolysed into an active metabolite – mycophenolic acid (MPA).
The MPA is a non-nucleoside, uncompetitive and reversible inosine
monophosphate dehydrogenase inhibitor, which participates in guano-
sine triphosphates de novo synthesis. As a consequence, MPA inhibits the
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proliferation of T and B lymphocytes, preventing
the acute rejection of a transplanted organ as well
as decreasing the frequency of late rejection after
one year and consecutive years [2, 3]. The MPA
undergoes enterohepatic recirculation. It is con-
verted into an inactive phenyl glucuronide (MPAG),
which is excreted into bile and hydrolysed into MPA
in the presence of β-glucuronidase, produced by
intestinal bacteria, and subsequently reabsorbed
in the intestines. It was found that, on average, the
enterohepatic recirculation takes part in about 40%
(10-60%) of the entire MPA exposure [4].
The MPA as well as MPAG pharmacokinetics
(PK) show great inter-patient variability depend-
ing on race, sex, concomitant clinical condition (e.g.
kidney or liver impairment, diseases with coexist-
ing hypoalbuminaemia), interactions with drugs
influencing the PK of MPA and MPAG, time elapsed
after renal transplantation and pharmacogenetic
factors [4-6]. 
The MPAG is eliminated mainly by the kidney
and the increase of its concentration may indi-
cate the deterioration of renal function. Compared
to patients with normal renal function, MPAG con-
centration in patients with impaired renal func-
tion is several times greater. Uncontrolled MPAG
concentration increase causes MPA displacement
from protein compounds and the increase of free
MPA, which might be the cause of higher phar-
macological activity of the drug and the intensi-
fication of its adverse effects. The influence of
renal failure on total MPA concentration is still
unclear. There are no unequivocal recommenda-
tions for MMF dosing in patients with renal fail-
ure [4, 7, 8]. 
The aim of the study was to analyse the influ-
ence of renal impairment on the PK of MPA and its
metabolite MPAG in renal transplant recipients.
Material and methods
Forty-three adult patients during the mainte-
nance period (> 6 months) following renal trans-
plantation receiving MMF in combination with
cyclosporine (CsA) (n = 21) or tacrolimus (Tac) 
(n = 22) and corticosteroids were considered. The
MMF dose varied from 0.50 g/day to 2.00 g/day and
was administered most often twice a day. The study
included patients with normal renal function 
(n = 16; creatinine clearance (Ccr) > 60 ml/min) and
with renal impairment (n = 27, Ccr < 60 ml/min).
Clinical characteristics of the patients are present-
ed in Table I. Blood samples were collected into
tubes containing EDTA at the following time points:
before the morning dose of MMF (C0), and subse-
quently 40 min, 1, 2, 3, 4 h after dosing.
Plasma MPA and MPAG concentrations were
determined using a high-performance liquid chro-
matography (HPLC) method described previously
[9, 10]. Briefly, the separation was performed using
a SupelcosilTM LC-18-DB column. The mobile phase
consisted of acetonitrile and orthophosphoric acid
(50 mmol/l) in a 50 : 50 ratio and indomethacin was
used as an internal standard. The MPAG plasma
concentration was estimated after MPAG enzymatic
hydrolysis into MPA in β-glucuronidase presence
(activity 89.4 U/ml). The MPAG concentrations were
Number of patients All (n = 43) Ccr > 60 ml/min (n = 17) Ccr < 60 ml/min (n = 26)
Male/female 23/20 11/6 12/14
CsA/Tac 21/22 8/9 13/13
Corticosteroid use 36 12 24
Proteinuria (yes/no) 9/34 1/16 8/18
Median (range)
Age [years] 44 (23-69) 44 (24-57) 44 (23-69)
Time after transplantation [years] 4.1 (0.6-10.9) 3.8 (0.6-10.8) 4.4 (1.2-10.9)
Body weight [kg] 74 (44-109) 75 (47-109) 73.5 (44-105)
Body mass index [kg/m2] 25.2 (16.1-36.8) 25.8 (21.2-36.5) 23.7 (16.1-36.8)
Body surface area [m2] 1.86 (1.37-2.35) 1.89 (1.37-2.35) 1.85 (1.39-2.22)
MMF dose [g/day] 1.50 (0.50-2.00) 1.00 (1.00-2.00) 1.50 (0.50-2.00)
CsA dose [mg/day] 175 (75-275) 162.5 (100-250) 175 (75-275)
Tac dose [mg/day] 4 (1-12) 4 (1-12) 4 (2-9)
Serum creatinine [mg/dl] 1.7 (0.8-4.8) 1.3 (0.8-1.7) 2.1 (1.0-4.8)*
Ccr [ml/min]** 53.7 (20.4-114.7) 75.2 (60.5-114.7) 44.9 (20.4-59.7)*
Ccr – creatinine clearance, CsA – cyclosporine, Tac – tacrolimus, MMF – mycophenolate mofetil, *p < 0.05, patients with Ccr > 60 ml/min 
vs. < 60 ml/min, Mann-Whitney test, **estimated by the Cockcroft-Gault equation
Table I. Characteristics of study patients
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calculated as a result of subtraction of MPA molar
concentration before the hydrolysis from MPA con-
centration after the enzymatic hydrolysis (CMPAG =
CMPA after enzymatic hydrolysis – CMPA before hydrolysis). The
MPAG was generously supplied by Roche Pharma-
ceuticals (Palo Alto, CA). 
The analysis method had a linear range of 
0.1-25.0 μg/ml and 10-250 μg/ml for MPA and
MPAG, respectively. Accuracy of MPA and MPAG
batches ranged from 97.4% to 106.4% and from
96.5% to 116.6%, respectively, and the precision,
expressed as the percentage of coefficient of vari-
ation (% CV), ranged from 0.8% to 6.9% and from
0.9% to 17.4%, respectively. 
The following PK parameters for MPA and MPAG
were calculated: pre-dose concentration (C0), 
maximum concentration (Cmax) and area under the
plasma concentration – time curve from 0 to 4 h
(AUC0-4 h) using the linear trapezoidal rule. Inter-
patient variability was assessed as % CV. Ccr was
estimated using the Cockcroft-Gault formula.
All statistical tests were performed using Sta-
tistica software version 8.0 and p value < 0.05
was considered significant. Chi-square test was
used for the evaluation of qualitative data. Nor-
mality was determined by Shapiro-Wilk W test.
Data were evaluated by the Mann-Whitney test
and Spearman correlation analysis. Multivariate
analysis was performed to evaluate the influence
of various clinical determinants on MPA and
MPAG PK parameters. For multivariate analysis
both PK parameters corrected and uncorrected
for MMF dose were examined. In the remaining
analyses only dose-corrected values were con-
sidered.
The study was performed following the recom-
mendations of the Declaration of Helsinki and
approved by the Bioethical Commission at the Poz-
nan University of Medical Sciences. Informed con-
sent was obtained from all patients prior to initi-
ating the study.
Results
The two groups of patients (with Ccr above or
below 60 ml/min) were comparable for sex, age,
time elapsed after renal transplantation, body
weight, MMF dose and for number of patients
receiving CsA or Tac. For groups with normal and
impaired renal function, medians of serum creati-
nine were 1.3 mg/dl and 2.1 mg/dl, respectively, and
median Ccr 75.2 ml/min and 44.9 ml/min, respec-
tively.
The MPA C0 values were significantly higher in
patients with impaired renal function than in
patients with normal renal function. However, 
AUC0-4 h and Cmax values were not significantly dif-
ferent between the two groups (Figure 1, Table II).
Moreover, the values of PK parameters for MPAG
(AUC0-4 h, C0 and Cmax) were also significantly 
higher in patients with impaired renal function
(Table II). Comparable differences for MPA and
MPAG PK parameters were observed between
groups in particular immunosuppressive regimens;
however, the differences for MPA C0 values were
barely significant (Table III).
In univariate analysis, MPAG PK parameters
(AUC0-4 h, C0, Cmax) were negatively correlated with
Ccr and positively correlated with serum creatinine
(Figure 2). Within MPA PK parameters, only C0 was
negatively correlated with Ccr and positively 
correlated with serum creatinine. Similar correlations
were found in particular immunosuppressive regi-
mens, although the serum creatinine correlation 
with MPA C0 in patients receiving MMF in combina-
tion with CsA was statistically insignificant (Table IV).
In multivariate analysis the results are consistent
with univariate analysis. Additionally, some MPA and
MPAG PK parameters were correlated with sex, CNI
co-administered and body weight. No correlations
with proteinuria were observed (Tables V and VI). 
For MPA and MPAG PK parameters, high CV val-
ues were observed, which in patients with impaired
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Figure 1. Dose-corrected (A) mycophenolic acid (MPA) and (B) mycophenolic acid glucuronide (MPAG) concentration-
time profiles classified by renal function (creatinine clearance (Ccr) > 60 ml/min vs. < 60 ml/ min). The results are
presented as median ± standard deviation. Concentrations are corrected to a daily dose of 1 g mycophenolate mofetil
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renal function exceeded 30% for all PK parameters
evaluated. The CV values were lower for MPA 
AUC0-4 h compared to MPA C0 (Table II).
Discussion
In our study we analysed the influence of renal
function on MPA and MPAG PK in patients during
the maintenance period following renal transplan-
tation. The concentrations of both MMF metabo-
lites (MPA and MPAG) varied widely, particularly in
patients with impaired renal function, despite MMF
dose correction. Similar variability was also pre-
sented by other authors [11-13].
Total drug exposure is best demonstrated by
AUC0-12 h. In clinical practice this parameter is diffi-
cult to assess, especially in patients treated in clin-
ics during the maintenance period following renal
transplantation. In our study, blood samples were
collected within 4 h after drug administration due
to the short duration of the patient’s stay in hos-
pital during a routine appointment in a transplant
PK – pharmacokinetic, MPA – mycophenolic acid, MPAG – 7-O-mycophenolic acid glucuronide, CV – coefficient of variation, Ccr – creatinine clear-
ance, AUC – area under the concentration-time curve, C0 – pre-dose concentration, Cmax – maximum concentration, *the results are presented
as median (range), **comparison between patients with Ccr > 60 ml/min and < 60 ml/min, Mann-Whitney test
Parameter All CV (%) Ccr > 60 ml/min CV (%) Ccr < 60 ml/min CV (%) Value of p**
(n = 43) (n = 17) (n = 26)
MPA
AUC0-4 h 19.40 31.0 19.01 23.4 21.25 34.7 0.285
[μg × h/ml] (8.71-35.46) (14.45-30.48) (8.71-35.46)
C0 [μg/ml] 1.93 60.4 1.48 43.3 2.24 55.6 0.010
(0.44-5.26) (0.44-2.39) (0.50-5.26)
Cmax [μg/ml] 10.35 40.9 10.35 42.0 10.07 39.9 0.650
(3.74-24.13) (5.50-24.13) (3.74-18.92)
MPAG
AUC0-4 h 235.68 57.0 172.47 29.3 299.94 47.8 < 0.001
[μg × h/ml] (112.67-857.26) (112.67-306.15) (170.11-857.26)
C0 [μg/ml] 36.44 72.9 29.65 41.8 61.01 60.8 < 0.001
(8.26-185.90) (8.26-53.63) (29.63-185.90)
Cmax [μg/ml] 68.21 58.2 50.94 27.6 103.92 47.6 < 0.001
(33.95-240.30) (33.95-87.49) (44.81-240.30)
Table II. Dose-corrected PK parameters* of MPA and MPAG classified by renal function
PK – pharmacokinetic, MPA – mycophenolic acid, MPAG – 7-O-mycophenolic acid glucuronide, Tac – tacrolimus, CsA – cyclosporine, Ccr – creati-
nine clearance, AUC – area under the concentration-time curve, C0 – pre-dose concentration, Cmax – maximum concentration, *the results are
presented as median (range), **comparison between patients with Ccr > 60 ml/min and < 60 ml/min, Mann-Whitney test
Tac (n = 22) Value of p* CsA (n = 21) Value of p**
Ccr > 60 ml/min Ccr < 60 ml/min Ccr > 60 ml/min Ccr < 60 ml/min
(n = 9) (n = 13) (n = 8) (n = 13)
MPA
AUC0-4 h 19.96 21.91 0.537 16.51 20.58 0.311
[μg × h/ml] (14.83-30.48) (11.83-35.46) (14.45-23.71) (8.71-32.47)
C0 [μg/ml] 1.98 2.46 0.037 1.11 1.90 0.060
(0.73-2.30) (0.76-5.26) (0.44-2.39) (0.50-4.37)
Cmax [μg/ml] 13.96 9.20 0.643 8.90 10.49 0.717
(5.50-24.13) (5.63-18.92) (6.20-18.08) (3.74-17.17)
MPAG
AUC0-4 h 189.06 298.05 0.014 168.36 359.29 0.002
[μg × h/ml] (112.67-229.25) (170.11-588.54) (124.12-306.15) (195.42-857.26)
C0 [μg/ml] 31.06 39.07 0.014 25.66 66.80 0.003
(10.70-42.47) (29.63-133.84) (8.26-53.63) (33.99-185.90)
Cmax [μg/ml] 50.94 100.43 0.021 52.13 115.50 0.002
(33.95-68.21) (44.81-226.41) (39.77-87.49) (61.67-240.30)
Table III. Dose-corrected PK parameters* of MPA and MPAG in patients treated with Tac or CsA classified by renal
function
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PK – pharmacokinetic, MPA – mycophenolic acid, MPAG – 7-O-mycophenolic acid glucuronide, Tac – tacrolimus, CsA – cyclosporine, AUC – area
under the concentration-time curve, C0 – pre-dose concentration, Cmax – maximum concentration
All (n = 43) Tac (n = 22) CsA (n = 21)
rp  rp  rp  
Creatinine clearance [ml/min]
MPA
AUC0-4 h [μg × h/ml] –0.023 0.886 0.068 0.763 –0.178 0.440
C0 [μg/ml] –0.406 0.007 –0.494 0.019 –0.460 0.036
Cmax [μg/ml] 0.202 0.194 0.289 0.193 0.043 0.854
MPAG
AUC0-4 h [μg × h/ml] –0.783 < 0.001 –0.668 < 0.001 –0.860 < 0.001
C0 [μg/ml] –0.793 < 0.001 –0.702 < 0.001 –0.849 < 0.001
Cmax [μg/ml] –0.724 < 0.001 –0.589 0.004 –0.848 < 0.001
Serum creatinine [mg/dl]
MPA
AUC0-4 h [μg × h/ml] –0.098 0.534 –0.078 0.730 –0.127 0.584
C0 [μg/ml] 0.333 0.029 0.494 0.020 0.208 0.365
Cmax [μg/ml] –0.258 0.095 –0.312 0.158 –0.152 0.510
MPAG
AUC0-4 h [μg × h/ml] 0.782 < 0.001 0.756 < 0.001 0.810 < 0.001
C0 [μg/ml] 0.739 < 0.001 0.691 < 0.001 0.762 < 0.001
Cmax [μg/ml] 0.713 < 0.001 0.625 0.002 0.816 < 0.001
Table IV. Spearman’s rank correlation between creatinine clearance or serum creatinine and PK parameters of MPA
and MPAG in patients treated with Tac or CsA
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Independent variables Relation Partial value of p Model value of p Model R coefficient
MPA C0 [mg/l]
Sex [men/women] NS 0.138 0.003 0.544
CNI [CsA/Tac] NS 0.064
MMF dose [g] Positive 0.022
Ccr [ml/min] Negative 0.008
MPA C0 [mg/l]
MMF dose [g] NS 0.075 0.033 0.435
Ccr [ml/min] NS 0.055
Proteinuria [yes/no] NS 0.562
MPA AUC0-4 h [mg × h/l]
Sex [men/women] Positive 0.017 < 0.001 0.593
MMF dose [g] Positive < 0.001
Ccr [ml/min] NS 0.694
MPA AUC0-4 h [mg × h/l]
MMF dose [g] Positive < 0.001 0.001 0.569
Ccr [ml/min] NS 0.420
Proteinuria [yes/no] NS 0.682
MPA Cmax [mg/l]
Body weight [kg] NS 0.055 0.007 0.438
MMF dose [g] Positive 0.002
Ccr [ml/min] Positive 0.039
MPA Cmax [mg/l]
MMF dose [g] Positive 0.001 0.003 0.532
Ccr [ml/min] Positive 0.046
Proteinuria [yes/no] NS 0.372
MPA C0 /dose [mg/l/g]
Sex [men/women] NS 0.173 < 0.001 0.565
CNI [CsA/Tac] Negative 0.007
Ccr [ml/min] Negative 0.004
MPA C0 /dose [mg/l/g]
Ccr [ml/min] Negative 0.042 0.098 0.323
Proteinuria [yes/no] NS 0.792
MPA AUC0-4 h/dose [mg × h/l/g]
Sex [men/women] Positive 0.017 0.015 0.449
CNI [CsA/Tac] NS 0.061
Ccr [ml/min] NS 0.613
MPA AUC0-4 h/dose [mg × h/l/g]
Ccr [ml/min] NS 0.565 0.582 0.159
Proteinuria [yes/no] NS 0.466
MPA Cmax/dose [mg/l]
Body weight [kg] Negative 0.012 0.036 0.332
Ccr [ml/min] NS 0.055
Table V. Multivariate analysis of clinical parameters influencing MPA PK parameters
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MPA – mycophenolic acid, PK – pharmacokinetic, C0 – pre-dose concentration, NS – not significant, CNI – calcineurin inhibitor, CsA – cyclosporine,
Tac – tacrolimus, MMF – mycophenolate mofetil, Ccr – creatinine clearance, AUC – area under the concentration-time curve, Cmax – maximum
concentration
Independent variables Relation Partial value of p Model value of p Model R coefficient
MPA Cmax/dose [mg/l]
Ccr [ml/min] NS 0.061 0.066 0.349
Proteinuria [yes/no] NS 0.307
Table V. Cont.
Independent variables Relation Partial value of p Model value of p Model R coefficient
MPAG C0 [mg/l]
Sex [men/women] Positive < 0.001 < 0.001 0.842
Body weight [kg] Positive < 0.001
MMF dose [g] Positive < 0.001
Ccr [ml/min] Negative < 0.001
MPAG C0 [mg/l]
MMF dose [g] Positive < 0.001 < 0.001 0.704
Ccr [ml/min] Negative < 0.001
Proteinuria [yes/no] NS 0.191
MPAG AUC0-4 h [mg × h/l]
Sex [men/women] Positive < 0.001 < 0.001 0.847
Body weight [kg] Positive < 0.001
MMF dose [g] Positive < 0.001
Ccr [ml/min] Negative < 0.001
MPAG AUC0-4 h [mg × h/l]
MMF dose [g] Positive < 0.001 < 0.001 0.681
Ccr [ml/min] Negative < 0.001
Proteinuria [yes/no] NS 0.526
MPAG Cmax [mg/l]
Sex [men/women] Positive < 0.001 < 0.001 0.832
Body weight [kg] Positive < 0.001
MMF dose [g] Positive < 0.001
Ccr [ml/min] Negative < 0.001
MPAG Cmax [mg/l]
MMF dose [g] Positive < 0.001 < 0.001 0.651
Ccr [ml/min] Negative 0.001
Proteinuria [yes/no] NS 0.689
MPAG C0/dose [mg/l/g]
Sex [men/women] Positive < 0.001 < 0.001 0.873
Body weight [kg] Positive < 0.001
CNI [CsA/Tac] Positive 0.047
Ccr [ml/min] Negative < 0.001
MPAG C0/dose [mg/l/g]
Ccr [ml/min] Negative < 0.001 < 0.001 0.661
Proteinuria [yes/no] NS 0.130
Table VI. Multivariate analysis of clinical parameters influencing MPAG PK parameters
Jolanta Kamińska, Maciej Głyda, Joanna Sobiak, Maria ChrzanowskaArch Med Sci 1, February / 2012 95
clinic. The MPA C0 is the most often used parame-
ter in clinical practice. Its value may be consider-
ably influenced by MPAG enterohepatic recircula-
tion, resulting in the second MPA plasma
concentration peak (Cmax2) approximately 6-12 h
after drug administration. In our study, higher MPA
C0 as well as MPAG C0, Cmax and AUC0-4 h values
were observed in patients with impaired renal func-
tion regardless of CNI used, whereas there were no
differences in the values of the other MPA PK
parameters (Cmax and AUC0-4 h). Elevated MPA C0
values may indicate intensified enterohepatic recir-
culation due to MPAG concentration increase in
patients with impaired renal function. The correla-
tions between renal function and MPAG concen-
trations as well as MPA C0 suggest that the cause
of the differences observed between two groups is
the dependence of MPAG concentration and indi-
rectly MPA C0 on renal function. The results con-
cerning MPAG are consistent with the literature.
However, the influence of renal function on MPA
PK parameters is still unclear. 
Similar results concerning MPA and MPAG PK
parameters were obtained by Gonzalez-Roncero et
al. [14]. The authors demonstrated not only the
influence of renal function on MPA C0 and MPAG
AUC but also its lack on MPA AUC. The studies by
Zanker et al. [15], Morgera et al. [16] and Weber et
al. [17] also observed higher MPAG AUC in renal
transplant recipients with lower Ccr than in patients
with normal glomerular filtration. However, values
of MPA AUC did not differ significantly. On the oth-
er hand, the results for MPA obtained by Moham-
madpur et al. [18] were different. According to this
study, significantly higher MPA AUC0-12 h values
along with unchanged C0 and significantly higher
MPA Cmax2 values were observed in patients with
impaired renal function. The authors also found
a negative correlation for Ccr and MPA AUC. The use
of abbreviated MPA profiles in our study may be
the reason for different AUC results compared with
the Mohammadpur et al. study. The abbreviated
profiles do not include MPA Cmax2 associated with
enterohepatic recirculation. In contrast to these
studies, van Hest et al. [19] and Weber et al. [20]
observed a total MPA concentration decrease in
patients with impaired renal function. It was sug-
gested that the concentration decrease was due to
the accumulation of MPAG, which displaced MPA
from its protein compounds, increasing free MPA
concentration and its clearance. The controversies
concerning the influence of renal failure on MPA
concentration values may be explained by Naesens
et al. [21]. The authors observed increased MPA and
MPAG concentration values in patients with mod-
erately reduced renal function (Ccr ranging from 
30 ml/min to 60 ml/min), whereas decreased total
MPA concentration values were observed in pa  -
tients with severe graft dysfunction (Ccr < 30 ml/
min), similarly as in the study by van Hest et al. [19].
This may explain the lack of differences in MPA
AUC0-4 h and Cmax values between groups with Ccr
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MPAG – 7-O-mycophenolic acid glucuronide, PK – pharmacokinetic, C0 – pre-dose concentration, CNI – calcineurin inhibitor, CsA – cyclosporine,
Tac – tacrolimus, MMF – mycophenolate mofetil, Ccr – creatinine clearance, NS – not significant, AUC – area under the concentration-time curve,
Cmax – maximum concentration
Independent variables Relation Partial value of p Model value of p Model R coefficient
MPAG AUC0-4 h/dose [mg × h/l/g]
Sex [men/women] Positive < 0.001 < 0.001 0.886
Body weight [kg] Positive < 0.001
CNI [CsA/Tac] Positive 0.015
Ccr [ml/min] Negative < 0.001
MPAG AUC0-4 h/dose [mg × h/l/g]
Ccr [ml/min] Negative < 0.001 < 0.001 0.583
Proteinuria [yes/no] NS 0.501
MPAG Cmax [mg/l]
Sex [men/women] Positive < 0.001 < 0.001 0.782
Body weight [kg] Positive < 0.001
Ccr [ml/min] Negative < 0.001
MPAG Cmax [mg/l]
Ccr [ml/min] Negative < 0.001 0.001 0.524
Proteinuria [yes/no] NS 0.861
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above or below 60 ml/min in our study, because
the group with impaired renal function included
patients with moderate as well as with severe graft
dysfunction. Nevertheless, our study showed 
higher MPA C0 values in patients with Ccr < 60 ml/
min, which may indicate intensified enterohepatic
recirculation in patients with impaired renal 
function as found in the study by Mohammadpur
et al. [18].
Proteinuria may also be considered as a factor
influencing MPA and MPAG PK parameters. Nae-
sens et al. [21] demonstrated correlations between
MPA PK parameters and proteinuria. However, in
our study in the multivariate analysis no relations
between MPA and MPAG PK parameters were
observed. It may be due to the small number of
patients (n = 9) with proteins determined in urine.
In conclusion, renal failure, irrespective of
immunosuppressive regimen, influences the MPAG
PK parameters and MPA C0 by increasing the val-
ues in patients with impaired renal function. The
results of our study indicate that solely MPA C0
determination in patients receiving MMF may be
insufficient in clinical practice because of great
inter-patient variability of this PK parameter caused
mainly by enterohepatic recirculation. It may lead
to wrong decisions concerning the pharmacother-
apy, particularly in patients with impaired renal
function. It seems to us that the monitoring of MPA
and MPAG AUC may allow MMF dosage regimens
to be optimized, and as a result improve the early
prevention of adverse effects in these patients.
Acknowledgments
This study was supported by Grant No. 501-02-
03306413-02324-50382 from Poznan University of
Medical Sciences. The authors declare no conflict
of interest.
References
1. Morris RG. Immunosuppressant drug monitoring: is the
laboratory meeting clinical expectations? Ann Pharma-
cother 2005; 39: 119-27.
2. Mamelok R. From mechanisms to long-term benefits.
Transplantation 2005; 79 (3 Suppl): S43-4.
3. Arns W. Noninfectious gastrointestinal (GI) complications
of mycophenolic acid therapy: a consequence of local GI
toxicity? Transplant Proc 2007; 39: 88-93.
4. Staatz CE, Tett SE. Clinical pharmacokinetics and phar-
macodynamics of mycophenolate in solid organ trans-
plant recipients. Clin Pharmacokinet 2007; 46: 13-58.
5. de Winter BC, Mathot RA, van Hest RM, van Gelder T.
Therapeutic drug monitoring of mycophenolic acid: does
it improve patient outcome? Expert Opin Drug Metab Tox-
icol 2007; 3: 251-61.
6. Morissette P, Albert C, Busque S, St-Louis G, Vinet B. In
vivo higher glucuronidation of mycophenolic acid in male
than in female recipients of a cadaveric kidney allograft
and under immunosuppressive therapy with mycophe-
nolate mofetil. Ther Drug Monit 2001; 23: 520-5.
7. Ting LS, Partovi N, Levy RD, Riggs KW, Ensom MH. Phar-
macokinetics of mycophenolic acid and its glucuronidat-
ed metabolites in stable lung transplant recipients. Ann
Pharmacother 2006; 40: 1509-16.
8. Pawiński T, Durlik M, Szlaska I, Urbanowicz A, Maj  chrzak J,
Gralak B. Comparison of mycophenolic acid pharmacoki-
netic parameters in kidney transplant patients within the
first 3 months post-transplant. J Clin Pharm Ther 2006;
31: 27-34. 
9. Seebacher G, Weigel G, Wolner E, et al. A simple HPLC
method for monitoring mycophenolic acid and its glu-
curonidated metabolite in transplant recipients. Clin Chem
Lab Med 1999; 37: 409-15.
10. Graj J, Chrzanowska M. Validation of HPLC method for
therapeutic drug monitoring of mycophenolic acid in renal
transplant recipients. Probl Ter Monit 2006; 1: 3-10.
11.  Liang MZ, Lu YP, Nan F, Li YP . Pharmacokinetics of
mycophenolic acid and its glucuronide after a single and
multiple oral dose of mycophenolate mofetil in Chinese
renal transplantation recipients. Transplant Proc 2006; 38:
2044-7.
12. Kuypers DR, Vanrenterghem Y, Squifflet JP, et al. Twelve-
month evaluation of the clinical pharmacokinetics of total
and free mycophenolic acid and its glucuronide metabo-
lites in renal allograft recipients on low dose tacrolimus
in combination with mycophenolate mofetil. Ther Drug
Monit 2003; 25: 609-22.
13. Ting LS, Partovi N, Levy RD, Riggs KW, Ensom MH. Phar-
macokinetics of mycophenolic acid and its phenolic-glu-
curonide and ACYI glucuronide metabolites in stable tho-
racic transplant recipients. Ther Drug Monit 2008; 30:
282-91.
14. González-Roncero FM, Gentil MA, Brunet M, et al. Phar-
macokinetics of mycophenolate mofetil in kidney trans-
plant patients with renal insufficiency. Transplant Proc
2005; 37: 3749-51.
15. Zanker B, Schleibner S, Schneeberger H, Krauss M, 
Land W. Mycophenolate mofetil in patients with acute
renal failure: evidence of metabolite (MPAG) accumula-
tion and removal by dialysis. Transpl Int 1996; 9: S308-10.
16. Morgera S, Budde K, Lampe D, et al. Mycophenolate
mofetil pharmacokinetics in renal transplant recipients
on peritoneal dialysis. Transpl Int 1998; 11: 53-7.
17. Weber LT, Lamersdorf T, Shipkova M, et al. Area under the
plasma concentration-time curve for total, but not for free,
mycophenolic acid increases in the stable phase after
renal transplantation: a longitudinal study in pediatric
patients. German Study Group on Mycophenolate Mofetil
Therapy in Pediatric Renal Transplant Recipients. Ther Drug
Monit 1999; 21: 498-506.
18. Mohammadpur AH, Nazemian F, Abtahi B, Naghibi M.
Influence of renal graft function on mycophenolic acid
pharmacokinetics during the early period after kidney
transplant. Exp Clin Transplant 2008; 6: 276-81.
19. van Hest RM, van Gelder T, Vulto AG, Shaw LM, Mathot
RA. Pharmacokinetic modelling of the plasma protein
binding of mycophenolic acid in renal transplant recipi-
ents. Clin Pharmacokinet 2009; 48: 463-76.
20. Weber LT, Shipkova M, Armstrong VW. The pharmacoki-
netic-pharmacodynamic relationship for total and free
mycophenolic acid in pediatric renal transplant recipients:
a report of the german study group on mycophenolate
mofetil therapy. J Am Soc Nephrol 2002; 13: 759-68.
21. Naesens M, de Loor H, Vanrenterghem Y, Kuypers DR. The
impact of renal allograft function on exposure and elim-
ination of mycophenolic acid (MPA) and its metabolite
MPA 7-O-glucuronide. Transplantation 2007; 84: 362-73.
Jolanta Kamińska, Maciej Głyda, Joanna Sobiak, Maria Chrzanowska